Listed

vTv Therapeutics Inc.

VTVTNasdaqCIK 1641489HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figureSign changed from a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$0Operating margin not reported
vTv Therapeutics Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001641489-25-000060.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure36.8Revenue, Q1 FY2026, three months to 2026-03-31$36.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001641489-26-000030.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)(28776.5%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)63.1%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $23.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Revenue: $36.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figurenot reported (Revenue of zero not reported)
Net margin%not reported (Revenue of zero not reported)(21376.5%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)65.5%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $24.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Revenue: $36.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001641489-26-000020.Report this figurenot reported (Revenue of zero not reported)
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$0Operating margin not reported
Free cash flow−$25.3m, FY2024
vTv Therapeutics Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m4.0Revenue, FY2021, twelve months to 2021-12-31$4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-13, accession 0001641489-24-000012.Report this figure2.0Revenue, FY2022, twelve months to 2022-12-31$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure0.0Revenue, FY2023, twelve months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure1.0Revenue, FY2024, twelve months to 2024-12-31$1.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure0.0Revenue, FY2025, twelve months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(540.9%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$21.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-13, accession 0001641489-24-000012.Revenue: $4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-13, accession 0001641489-24-000012.Report this figure(1116.9%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$22.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-20, accession 0001641489-25-000014.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figurenot reported (Revenue of zero not reported)(2377.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$24.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010.Revenue: $1.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figurenot reported (Revenue of zero not reported)
Net margin%(324.3%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-13, accession 0001641489-24-000012.Revenue: $4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-13, accession 0001641489-24-000012.Report this figure(949.7%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$19.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-20, accession 0001641489-25-000014.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figurenot reported (Revenue of zero not reported)(1815.3%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$18.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001641489-26-000010.Revenue: $1.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001641489-26-000010.Report this figurenot reported (Revenue of zero not reported)
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(19.3)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$19.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-13, accession 0001641489-24-000012.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-13, accession 0001641489-24-000012.Report this figure(16.0)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$16.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-20, accession 0001641489-25-000014.Capital expenditure: $21.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure(19.1)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$19.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001641489-26-000010.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figure(25.3)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$25.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001641489-26-000010.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001641489-25-000014.Report this figurenot reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding vTv Therapeutics Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
SAMSARA BIOCAPITAL, LLC2026-06-30$11.2m298,496Unchanged
MILLENNIUM MANAGEMENT LLC2026-06-30$10.2m269,874Added+63,586
FMR LLC2026-06-30$9.8m260,391Unchanged
Siren, L.L.C.2026-06-30$6.1m163,000Unchanged
BAKER BROS. ADVISORS LP2026-06-30$5.6m148,314Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$3.6m94,463Reduced−14,459
Trails Edge Capital Partners, LP2026-06-30$3.2m85,192Reduced−54,386
Aisling Capital Management LP2026-06-30$1.9m50,000New+50,000
MARSHALL WACE, LLP2026-06-30$1.5m39,560Added+26,171
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$1.2m32,470Reduced−416

Recent filings

All 594 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

vTv Therapeutics Inc., recent filings
FiledFormWhat it isAccession number
2026-10-0620:31 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001641489-26-000032
2026-08-0620:24 ET10-QQuarterly reportPeriod 2026-06-300001641489-26-000030
2026-08-0620:18 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001641489-26-000029
2026-06-2920:14 ET8-K5.07 Shareholder vote results0001641489-26-000024
2026-05-1321:20 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-221971
2026-05-1320:21 ET10-QQuarterly reportPeriod 2026-03-310001641489-26-000020
2026-05-1320:18 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001641489-26-000019
2026-04-2820:21 ETDEF 14AProxy statementPeriod 2026-06-100001641489-26-000015
2026-03-1020:37 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001641489-26-000012
2026-03-1020:35 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001641489-26-000011

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 10, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1641489
Tickers
VTVT
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.